Alnylam Pharmaceuticals (ALNY) Asset Utilization Ratio (2010 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Asset Utilization Ratio for 17 consecutive years, with 0.9 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Asset Utilization Ratio rose 107.95% year-over-year to 0.9; the trailing twelve-month figure through Jun 2026 stood at 0.9 (up 107.95% YoY), and the FY2025 full-year result was 0.81, up 44.8% from the prior year.
• Asset Utilization Ratio grew to 0.9 in Q2 2026 per ALNY's latest filing, from 0.85 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.9 in Q2 2026 and bottomed at 0.25 in Q1 2022.
• Historically, Asset Utilization Ratio has averaged 0.48 across 5 years, with a median of 0.48 in 2023.
• The sharpest annual moves came in 2025 and 2026: Asset Utilization Ratio slipped 27.77% in 2025, then surged 107.95% in 2026.
• Over 5 years, Asset Utilization Ratio stood at 0.29 in 2022, then surged by 62.74% to 0.48 in 2023, then advanced by 11.67% to 0.53 in 2024, then rose by 20.51% to 0.64 in 2025, then soared by 40.11% to 0.9 in 2026.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.9, 0.85, and 0.64 for Q2 2026, Q1 2026, and Q4 2025 respectively.